Picture of Mabion SA logo

MAB Mabion SA Share Price

0.000.00%
pl flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m-9.04%
3m-18.59%
6m-16.9%
1yr-24.61%
Volume Change (%)
10d/3m-59.05%
Price vs... (%)
52w High-31.19%
50d MA-9.06%
200d MA-8.48%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)81.2
PEG Ratio (f)n/a
EPS Growth (f)-93.33%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value2.43
Price to Tang. Book2.44
Price to Free Cashflow7.9
Price to Sales1.67
EV to EBITDA3.76

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital37.47%
Return on Equity48.65%
Operating Margin34.09%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Mabion SA EPS forecast chart

Profile Summary

Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
October 29th, 2009
Public Since
August 10th, 2010
No. of Employees
255
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
pl flag iconWarsaw Stock Exchange
Shares in Issue
16,162,326
Blurred out image of a map
Address
gen. Mariana Langiewicza 60, KONSTANTYNOW LODZKI, 95-050
Web
https://www.mabion.eu/
Phone
+48 422077890
Contact
Marek Bugdol
Auditors
PricewaterhouseCoopers Polska sp. z o.o. Audyt sp.k.

MAB Share Price Performance

Upcoming Events for MAB

Full Year 2023 Mabion SA Earnings Release

Q1 2024 Mabion SA Earnings Release

Mabion SA Annual Shareholders Meeting

Half Year 2024 Mabion SA Earnings Release

Similar to MAB

Picture of Airway Medix SA logo

Airway Medix SA

pl flag iconWarsaw Stock Exchange

Picture of Bioton SA logo

Bioton SA

pl flag iconWarsaw Stock Exchange

Picture of Braster SA logo

Braster SA

pl flag iconWarsaw Stock Exchange

Picture of Captor Therapeutics SA logo

Captor Therapeutics SA

pl flag iconWarsaw Stock Exchange

Picture of E-Shopping SA logo

E-Shopping SA

pl flag iconWarsaw Stock Exchange

FAQ